Beranda › Penyakit Crohn › Massachusetts › New Bedford
Uji klinis Penyakit Crohn di New Bedford, MA
6 studi untuk Penyakit Crohn mencari peserta di lokasi sekitar New Bedford (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
Menerima pesertaFase 2
- Lucida Clinical Trials /ID# 282000, New Bedford
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
Menerima pesertaFase 4
- Lucida Clinical Trials LLC, New Bedford
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Menerima pesertaFase 2
- Lucida Clinical Trials /ID# 266548, New Bedford
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Menerima pesertaFase 3
- Lucida Clinical Trials, New Bedford
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Menerima pesertaFase 3
- Lucida Clinical Trials, New Bedford
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Menerima pesertaFase 2
- Lucida Clinical Trials, LLC, New Bedford
Uji klinis Penyakit Crohn di kota lain
- New York City, NY35 studi
- Boston, MA19 studi
- Miami, FL19 studi
- Cleveland, OH19 studi
- St. Louis, MO19 studi
- Tyler, TX17 studi
- Houston, TX17 studi
- Orlando, FL17 studi
- Atlanta, GA17 studi
- San Antonio, TX15 studi
- San Diego, CA15 studi
- Los Angeles, CA15 studi
Studi lain di New Bedford
- Obesitas7 studi
- Kelebihan Berat Badan7 studi
- PPOK4 studi
- Diabetes Tipe 23 studi
- Penyakit Alzheimer3 studi
- Kolitis Ulseratif3 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.